Provided by Tiger Trade Technology Pte. Ltd.

ETF & Stock Investment

2,096.82
-0.1118-0.01%
Number of Gainers:505
Number of Losers:488
Number of Flat:28
PE:- -
High:2,100.64
Open:2,096.97
Low:2,093.04
Close:2,096.93
Volume:5.03B
Turnover:643.03B
Market Cap:97.53T
Float Cap:91.30T

Loading ...

Treasury Yields Resume Upward Trend

Dow Jones
·
Oct 02

Press Release: PNC Declares Dividend of $2.00 on Common Stock

Dow Jones
·
Oct 02

Market Chatter: KKR, Blackstone Among Potential Bidders for Cary Group

MT Newswires Live
·
Oct 02

Signaux Girod Reports 1,032,500 Issued Shares as of Sept. 30, 2026

Reuters
·
Oct 02

G-III Growth Seen Constrained by PVH Brands Phaseout, Higher Costs, UBS Says

MT Newswires Live
·
Oct 02

Update: BofA Securities Adjusts Nike Price Target to $24 From $30, Maintains Underperform Rating

MT Newswires Live
·
Oct 02

NVIDIA Launches 64GB DGX Spark With Halved Memory Starting at $4,999, While 128GB Version Jumps to $6,950

Deep News
·
Oct 02

Market Chatter: UBS Engages With Nordea Bank Over Potential Switzerland Exit

MT Newswires Live
·
Oct 02

US-Listed ETFs on Course for Record Annual Inflows, State Street Says

Reuters
·
Oct 02

McCormick's Near-Term Catalyst Path is Choppy, UBS Says

MT Newswires Live
·
Oct 02

General Mills Holds Annual Shareholder Meeting

Reuters
·
Oct 02

California, New York and 24 Other States, Counties and Cities Sue Trump Administration over Vehicle Fuel Economy Rollback Rule

THOMSON REUTERS
·
Oct 02

Expeditors International of Washington Seen Benefiting From Stronger Ocean Rates, Airfreight Growth, UBS Says

MT Newswires Live
·
Oct 02

Can Google's New Flagship Model Finally Match OpenAI and Anthropic at the Frontier?

Deep News
·
Oct 02

NASDAQ New 52-Week Highs and Lows

Dow Jones
·
Oct 02

Biogen Says Litifilimab Posts Sustained Skin Clearance in 52-Week Phase 2 Cutaneous Lupus Study

Reuters
·
Oct 02

Biogen - 28.8% of Participants Achieve 70% or Greater Reduction in Clasi a at Week 52

THOMSON REUTERS
·
Oct 02

Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 Amethyst Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus~

THOMSON REUTERS
·
Oct 02

Biogen - Serious Adverse Events Occurred in 3.4% of Participants During 52-Week Treatment Period

THOMSON REUTERS
·
Oct 02

Biogen - 33.7% of Crossover Participants Report Clear or Almost Clear Skin at Week 52

THOMSON REUTERS
·
Oct 02